type here...

David Egilman, Gregory Collins, Julie Falender, Naomi Shembo, Ciara Keegan, Sunil Tohan

David Egilman is a Clinical Professor of Family Medicine at Brown University. He is board-certified in internal medicine and preventive and occupational medicine and an epidemiologist, and the past Editor in Chief of the International Journal of Occupational and Environmental Health and current Editor of The Journal of Scientific Practice and Integrity.
Antitrust and Competition

The Rise of the Opioids: How Purdue Invented New Markets for OxyContin

David Egilman, Gregory Collins, Julie Falender, Naomi Shembo, Ciara Keegan, Sunil Tohan
Purdue's strategy was to market its opioids directly to patients via brochures, videos, advertisements, and the internet. It also provided information to doctors and...
Academic Capture

Purdue Circumvented the Regulator to Promote OxyContin, Hiding Its Real Risk of Addiction

David Egilman, Gregory Collins, Julie Falender, Naomi Shembo, Ciara Keegan, Sunil Tohan
In 2001, the Food and Drug Administration required Purdue to change OxyContin’s patient package inserts to make addiction risks more evident. The company altered...
Academic Capture

OxyContin's Academic Marketing: The Studies That Fueled the Opioid Crisis

David Egilman, Gregory Collins, Julie Falender, Naomi Shembo, Ciara Keegan, Sunil Tohan
Purdue Pharmaceuticals used to cite three major studies to argue that in prescribing OxyContin, addiction-risk was not significant. The most influential of those studies...

Latest news

View All

The publication of the Stigler Center at The University of Chicago Booth School of Business

ProMarket is dedicated to discussing how competition tends to be subverted by special interests. The posts represent the opinions of their writers, not necessarily those of the University of Chicago, the Booth School of Business, or its faculty. For more information, please visit ProMarket Policy.